目的 探討四神丸聯(lián)合美沙拉秦治療潰瘍性結(jié)腸炎的臨床療效。方法 選取濮陽市人民醫(yī)院2016年1月—2017年6月收治的潰瘍性結(jié)腸炎活動期患者184例，隨機(jī)分為對照組和治療組，每組各92例。對照組患者口服美沙拉秦緩釋顆粒，1 g/次，3次/d；治療組患者在對照組基礎(chǔ)上口服四神丸，9 g/次，3次/d。兩組患者均治療12周。觀察兩組患者臨床療效，比較治療前后兩組患者血紅蛋白（Hgb）、血沉（ESR）、C-反應(yīng)蛋白（CRP）、前列腺素E2（PGE2）、白三烯B4（LTB4）和血小板活動因子（PAF）水平及Mayo積分和每日平均腹瀉次數(shù)。結(jié)果 治療后，對照組和治療組臨床總有效率分別為71.17%、89.13%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者Hgb明顯升高，ESR和CRP水平明顯降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后治療組患者ESR和CRP水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者PGE2、LTB4和PAF水平均明顯降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者PGE2和LTB4水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者M(jìn)ayo評分和每日腹瀉次數(shù)均較治療前明顯降低，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療后治療組患者M(jìn)ayo評分和每日腹瀉次數(shù)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 四神丸聯(lián)合美沙拉秦可以有效改善潰瘍性結(jié)腸炎患者臨床癥狀，控制炎癥，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy and safety of Sishen Pills combined with mesalazine in treatment of ulcerative colitis. Methods Patients (184 cases) with ulcerative colitis in Puyang People's Hospital from January 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 92 cases. Patients in the control group were po administered with Mesalazine Sustained Release Granules, 1 g/time, three times daily. Patients in the treatment group were po administered with Sishen Pills on the basis of the control group, 9 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy was evaluated, the Hgb, ESR, CRP, PGE2, LTB4 and PAF levels, the Mayo scores and frequency of diarrhea in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 71.17% and 89.13% respectively, and there were differences between two groups (P < 0.05). After treatment, the Hgb level in two groups was significantly increased, but ESR and CRP level was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the ESR and CRP level in the treatment group after treatment was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, PGE2, LTB4 and PAF level in two groups was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the PGE2, LTB4 level in the treatment group after treatment was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the Mayo scores and frequency of diarrhea in two groups was significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these indexes in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Sishen Pills combined with mesalazine can effectively improve the clinical symptoms in treatment of ulcerative colitis, and effectively control inflammation, which has a certain clinical application value.